SCHEMBL5887218

SCHEMBL5887218

COc1ccc(C2=C(C(F)(F)F)[CH]CC=C2c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.46
BACE1 P56817 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CA4 P22748 1/20 0.36
TP53 P04637 1/20 0.36
MCL1 Q07820 1/20 0.35
TNK2 Q07912 1/20 0.34
PGR P06401 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10401569 0.80 KIF11 (0.36) BACE1ALDH1A1
SCHEMBL5887361 0.79 RAD51 (0.40) SMN1; SMN2CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL5887421 0.78 LTA4H (0.44) LTA4HBACE1SMN1; SMN2HPGDL3MBTL1
SCHEMBL5887387 0.76 LTA4H (0.51) LTA4HBACE1SMN1; SMN2L3MBTL1MAPT
SCHEMBL5887161 0.76 LTA4H (0.42) LTA4HBACE1SMN1; SMN2HPGDL3MBTL1
SCHEMBL5887293 0.75 LTA4H (0.50) LTA4HBACE1SMN1; SMN2L3MBTL1MAPT
SCHEMBL5887299 0.74 LTA4H (0.43) LTA4HBACE1SMN1; SMN2HPGDL3MBTL1
SCHEMBL5887002 0.74 LTA4H (0.49) LTA4HBACE1SMN1; SMN2L3MBTL1MAPT
SCHEMBL5887281 0.74 LTA4H (0.49) LTA4HBACE1SMN1; SMN2HPGDL3MBTL1
SCHEMBL5887277 0.71 LTA4H (0.45) LTA4HBACE1SMN1; SMN2HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R LTA4H 3106/4885BACE1 944/4885SMN1; SMN2 1459/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R LTA4H 3360/4885BACE1 1420/4885SMN1; SMN2 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.